Sign in

    Ron Leger

    Research Analyst at England Alternatives Investments

    Ron Leger is a Research Analyst at England Alternatives Investments, primarily covering companies such as EOM Pharmaceutical. His track record reflects limited but targeted coverage, with participation in earnings calls and direct engagement in company analysis. Leger began his tenure at England Alternatives Investments in a research capacity, with no prior publicly documented investment firm affiliations and no available third-party performance metrics or rankings. At present, there are no officially published professional credentials, securities licenses, or notable industry recognitions associated with his profile.

    Ron Leger's questions to EOM Pharmaceutical Holdings (IMUC) leadership

    Ron Leger's questions to EOM Pharmaceutical Holdings (IMUC) leadership • Q3 2016

    Question

    Ron Leger from England Alternatives Investments asked for details on the increased competition for glioblastoma patients, the specifics of loosening the ICT-107 trial's screening criteria, and the level of partnership interest from large pharmaceutical companies.

    Answer

    CEO Andrew Gengos identified Bristol Myers Squibb's large Opdivo trials as a key source of competition, which may attract patients who prefer not to wait or undergo apheresis. He explained that screening criteria were loosened for patients post-chemo-radiation because MRIs can be difficult to interpret, and the previous standard was too stringent. Regarding partnerships, Gengos stated that while dialogues are active, large pharma companies seem to be in a 'wait-and-see' mode, wanting more definitive data before committing, despite the logical therapeutic combination with checkpoint inhibitors.

    Ask Fintool Equity Research AI